1. Levine A, Koletzko S, Turner D, et al. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr. 2014; 58:795–806.
Article
2. Ho SSC, Keenan JI, Day AS. Parent perspectives of diagnostic and monitoring tests undertaken by their child with inflammatory bowel disease. Pediatr Gastroenterol Hepatol Nutr. 2021; 24:19–29.
Article
3. Deutschmann C, Sowa M, Murugaiyan J, et al. Identification of chitinase-3-like protein 1 as a novel neutrophil antigenic target in Crohn’s disease. J Crohns Colitis. 2019; 13:894–904.
Article
4. Ho SSC, Keenan JI, Day AS. The role of gastrointestinal-related fatty acid-binding proteins as biomarkers in gastrointestinal diseases. Dig Dis Sci. 2020; 65:376–390.
Article
5. Ho SS, Wall C, Gearry RB, Keenan J, Day AS. A pilot study evaluating novel urinary biomarkers for Crohn’s disease. Inflamm Intest Dis. 2020; 5:212–220.
Article
6. Koutroubakis IE, Petinaki E, Dimoulios P, et al. Increased serum levels of YKL-40 in patients with inflammatory bowel disease. Int J Colorectal Dis. 2003; 18:254–259.
Article
7. Vind I, Johansen JS, Price PA, Munkholm P. Serum YKL-40, a potential new marker of disease activity in patients with inflammatory bowel disease. Scand J Gastroenterol. 2003; 38:599–605.
8. Wewer V, Riis L, Vind I, et al. Serum YKL-40 in children with inflammatory disease compared to healthy children. J Pediatr Gastroenterol Nutr. 2004; 39:S284.
9. Kim HH, Chung MH, Bin JH, Cho KS, Lee J, Suh JS. Urinary YKL-40 as a candidate biomarker for febrile urinary tract infection in young children. Ann Lab Med. 2018; 38:39–45.
Article
10. Logan M, MacKinder M, Clark CM, et al. Intestinal fatty acid binding protein is a disease biomarker in paediatric coeliac disease and Crohn’s disease. BMC Gastroenterol. 2022; 22:260.
Article